Adaptogenics Health Corp. (CSE: ADPT) has announced a strategy to acquire, design, and advance proprietary peptide and small molecule assets supported by differentiated delivery technologies, targeting opportunities in metabolic health, muscle preservation, and healthy ageing. The Vancouver-based company is operating under the leadership of CEO Dr. J. David Warren, a medicinal chemist with more than two decades of experience in peptide science and translational drug discovery. The announcement also confirms a new Chief Financial Officer appointment and a market-making services agreement, signalling a broader operational reconfiguration that investors may be watching closely.

Key Points

  • Adaptogenics Health Corp. (CSE: ADPT) announced a proprietary peptide and small molecule asset development strategy on October 19, 2026.
  • The company intends to acquire and license therapeutic assets, design proprietary molecules, and advance delivery technologies across metabolic health and muscle preservation programs.
  • Steven Nguyen, CPA, has been appointed CFO; Generation IACP Inc. engaged as market maker at C$8,500 per month plus taxes for an initial six-month term.
  • Investors may watch for progress on GLP-1 companion product evaluations and the development of defensible intellectual property around peptide candidates.

Adaptogenics' Scientific Focus: Peptides, Delivery Technology, and GMP Standards

The company's strategy centres on four key activities: acquiring and exclusively licensing therapeutic assets, designing proprietary molecules through analogue programs, developing delivery technologies to improve peptide stability and administration, and building research programs around defined biological endpoints. Initial areas of interest include metabolic health, muscle preservation, mitochondrial biology, and inflammation resolution. Adaptogenics states it intends to source peptide material from qualified GMP manufacturers and use independent third-party laboratories to verify identity, purity, and other critical quality attributes, establishing what the release describes as a reliable scientific foundation.

Dr. Warren's Background and the Elamipretide Connection

CEO Dr. J. David Warren brings over two decades of experience in medicinal chemistry and peptide science. The release states his published research includes foundational mechanistic work on SS-31, now known as elamipretide, a mitochondria-targeted peptide later developed as Forzinity and granted accelerated FDA approval to improve muscle strength in patients with Barth syndrome weighing at least 30 kg. The company also states it is evaluating GLP-1 companion products intended to address muscle loss, nutritional deficiencies, and reduced physical function associated with medical weight loss programs, complementing its longer-term proprietary pipeline ambitions.

CFO Transition and Market-Making Engagement at ADPT

Adaptogenics has appointed Steven Nguyen, CPA, as its new Chief Financial Officer, replacing Ming Jang. Nguyen is described as Managing Principal of Corporate Minds Inc., which provides back-office solutions to public venture issuers. Separately, the company has engaged Generation IACP Inc. to provide market-making services on the Canadian Securities Exchange commencing October 19, 2026. The agreement carries a monthly fee of C$8,500 plus applicable taxes, subject to an annual 3% increase, with an initial six-month term that renews automatically. The release confirms Generation holds no securities of the company and the two entities are unrelated.